E2F8 and gallbladder cancer: This study identifies the E2F8-RRM2 axis as pivotal mechanism underlying gemcitabine resistance in gallbladder cancer and demonstrates that targeting E2F8 significantly enhances tumor sensitivity to PARP inhibition.